{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Par Drugs & Chemicals Ltd
Par Drugs & Chemicals Q3 FY26: Strong Profit Surge Masks Troubling Long-Term Trajectory
Par Drugs and Chemicals Ltd., a micro-cap chemical manufacturer with a market capitalisation of ₹124.83 crores, delivered a robust quarterly performance in Q3 FY26, posting net profit of ₹4.80 crores—a sharp 16.23% quarter-on-quarter increase and a remarkable 727.59% year-on-year surge. However, this impressive quarterly snapshot conceals deeper structural concerns that have plagued the company's long-term trajectory, with the stock down 41.57% over the past year despite the recent operational uptick.
Are Par Drugs & Chemicals Ltd latest results good or bad?
Par Drugs & Chemicals Ltd's latest results show a quarter-on-quarter profit increase of 24.02% and improved operating margins, but year-on-year declines in both revenue and profit highlight ongoing operational challenges, indicating a fragile recovery.
Par Drugs & Chemicals Ltd Valuation Shifts to Fair Amid Mixed Market Performance
Par Drugs & Chemicals Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions and sector dynamics. Despite a recent 5.2% intraday price gain, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more cautious outlook compared to its historical benchmarks and peer group averages.
Par Drugs & Chemicals Ltd is Rated Sell
Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.
Par Drugs & Chemicals Ltd: Valuation Shifts Signal Changing Price Attractiveness
Par Drugs & Chemicals Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating as of early 2026. This change reflects evolving market perceptions amid subdued price performance and relative sector dynamics, prompting investors to reassess the stock’s price attractiveness compared to historical and peer benchmarks.
Par Drugs & Chemicals Ltd is Rated Sell
Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Par Drugs & Chemicals Ltd is Rated Sell
Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Par Drugs & Chemicals Ltd is Rated Sell
Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Par Drugs & Che. Sees Revision in Market Assessment Amid Mixed Financial Signals
Par Drugs & Che., a microcap player in the Chemicals & Petrochemicals sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This development comes amid a volatile performance trajectory and evolving market conditions.
Is Par Drugs & Che. overvalued or undervalued?
As of November 17, 2025, Par Drugs & Chemicals is fairly valued with a PE ratio of 11.95 and an EV to EBIT of 8.99, significantly lower than its expensive peers, but has underperformed the Sensex with a stock return of -65.29%.
Par Drugs & Chemicals Q2 FY26: Profit Rebound Masks Underlying Margin Pressure
Par Drugs and Chemicals Ltd., a micro-cap speciality chemicals manufacturer based in Gujarat, reported a sequential profit recovery in Q2 FY26, with net profit climbing to ₹4.13 crores from ₹3.33 crores in the previous quarter. However, the year-on-year comparison reveals a more sobering reality: profits plunged 51.98% from ₹8.60 crores in Q2 FY25, whilst the company's stock has witnessed a brutal correction, trading at ₹93.70—down 73.11% from its 52-week high of ₹348.45.
How has been the historical performance of Par Drugs & Che.?
Par Drugs & Che. has shown consistent growth in net sales and profits, with net sales increasing from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25, and profit after tax reaching 13.36 Cr in Mar'25. Despite rising costs and cash flow challenges, the company maintains a healthy profit margin of 13.23%.
Why is Par Drugs & Che. falling/rising?
As of 07-Nov, Par Drugs & Chemicals Ltd's stock price is declining at 98.73, down 0.45% and significantly underperforming its sector. The company has reported negative results for three consecutive quarters, contributing to a 50.36% year-to-date decline, despite a low debt-to-equity ratio and modest sales growth.
Why is Par Drugs & Che. falling/rising?
As of 26-Sep, Par Drugs & Chemicals Ltd's stock price is at 104.06, down 4.07%, and has significantly underperformed its sector and the broader market. The company has faced declining profits over the past three quarters and shows weak long-term growth prospects, contributing to a year-to-date stock decline of 47.68%.
Why is Par Drugs & Che. falling/rising?
As of 24-Sep, Par Drugs & Chemicals Ltd is currently priced at 110.95, reflecting a 1.72% increase. Despite a significant 53.05% decline over the past year, the stock shows short-term resilience and an attractive valuation, outperforming its sector by 2.21%.
Why is Par Drugs & Che. falling/rising?
As of 23-Sep, Par Drugs & Chemicals Ltd's stock price is 109.07, down 2.98%, and has significantly underperformed its sector and the broader market. The company faces ongoing challenges with negative quarterly results and a year-to-date decline of 45.16%, indicating poor long-term growth prospects despite some favorable valuation metrics.
Why is Par Drugs & Che. falling/rising?
As of 22-Sep, Par Drugs & Chemicals Ltd's stock price is 112.42, down 0.22%, despite recent short-term gains of 6.29% and 13.87% over the past week and month. However, the stock has significantly underperformed over the year with a decline of 53.87%, raising concerns about its long-term growth outlook due to negative quarterly results and falling profits.
Why is Par Drugs & Che. falling/rising?
As of 19-Sep, Par Drugs & Chemicals Ltd's stock price is at 112.67, down 4.97%, and has underperformed its sector. Despite a recent positive return of 3.71% over the past week, the stock has declined 51.86% over the past year, indicating waning investor confidence amid poor long-term growth and negative quarterly results.
Par Drugs & Chemicals Faces Trading Challenges Amidst Significant Market Activity
Par Drugs & Chemicals Ltd, a microcap in the Chemicals & Petrochemicals sector, faced notable trading activity as its stock reached the lower circuit limit. The stock's performance was below the sector average, with mixed trends in moving averages and a significant decline in its 1-day return.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
